Photopharmics
Salt Lake City, US · Founded 2011 · Delaware corporation · 1 known investors
PhotoPharmics develops Celeste, an investigational photo-neuromodulation device being evaluated in clinical trials for Parkinson's disease. The non-invasive, home-based device delivers light through the eyes to explore the role of retinal and circadian signaling pathways in addressing motor and non-motor symptoms of Parkinson's disease.
Founders & leadership
KS
Kent SavageExecutive Officer, Director
TS
Ted StanleyDirector
GC
Gavin ChristensenDirector
DA
Daniel AdamsDirector
Investors · 1
Competitors · 6
by search overlapDiabetes Prevention Program148 shared keywords
Cleveland Clinic, 2022126 shared keywordsCleveland Clinic is a patient-centered academic medical center providing clinical care, research, and medical education. The organization offers services ranging from primary care and virtual visits to specialized treatment, clinical trials, and advanced medical research.
Healthline124 shared keywordsHealthline publishes medically reviewed health and wellness content for general consumers, drawing on a network of medical reviewers. It operates as a consumer health media and information platform.
Mayo Clinic123 shared keywords
Stanford blockchain101 shared keywords
Dervan et al59 shared keywords
Companies competing with Photopharmics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$26.2MraisedNov 2025 · 47 investors · BiotechnologyRule 506(b)
▶$26.2MraisedNov 2025 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gavin ChristensenDirector
- Kent SavageExecutive Officer, Director
- Daniel AdamsDirector
- Offering amount
- $26.3M
- Amount sold
- $26.2M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedDec 2020 · 9 investors · Other TechnologyRule 506(b)
▶$2.5MraisedDec 2020 · 9 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Gavin ChristensenDirector
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedOct 2019 · 24 investors · Other TechnologyRule 506(b)
▶$6.6MraisedOct 2019 · 24 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Gavin ChristensenDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedMar 2017 · 18 investors · Other TechnologyRule 506(b)
▶$2.7MraisedMar 2017 · 18 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Kent SavageExecutive Officer, Director
- Ted StanleyDirector
- Gavin ChristensenDirector
- Daniel AdamsDirector
- Offering amount
- $2.8M
- Amount sold
- $2.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2017 · 15 investors · Other TechnologyRule 506(b)
▶$2.3MraisedFeb 2017 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ted StanleyDirector
- Gavin ChristensenDirector
- Kent SavageExecutive Officer, Director
- Daniel AdamsDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJul 2015 · 15 investors · Other TechnologyRule 506(b)
▶$2.1MraisedJul 2015 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Ted StanleyDirector
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Gavin ChristensenDirector
- Offering amount
- $2.7M
- Amount sold
- $2.1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $320K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
- Photopharmics closes $6 million to advance Parkinson’s devicelongevity.technology · 2025
- Photopharmics raises $6M for Parkinson's light therapy deviceparkinsonsnewstoday.com · 2025